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ABSTRACT
Tight junction protein 1 (TJP1) has recently been proposed as a biomarker 
to identify multiple myeloma (MM) patients most likely to respond to bortezomib- 
and carfilzomib-based proteasome inhibitor regimens. Herein we report increased 
expression of TJP1 during the adaptive response mediating carfilzomib resistance in 
the LP-1/Cfz MM cell line. Moreover, increased TJP1 expression delineated a subset of 
relapsed/refractory MM patients on bortezomib-based therapy sharing an LP-1/Cfz-
like phenotype characterized by activation of interacting transcriptional effectors of 
the Hippo signaling cascade (TAZ and TEAD1) and an adult tissue stem cell signature. 
siRNA-mediated knockdown of TJP1 or TAZ/TEAD1 partially sensitized LP-1/Cfz 
cells to carfilzomib. Connectivity Map analysis identified translation inhibitors as 
candidate therapeutic agents targeting this molecular phenotype. We confirmed this 
prediction by showing that homoharringtonine (omacetaxine mepesuccinate) — the 
first translation inhibitor to be approved by the U.S. Food and Drug Administration — 
displayed potent cytotoxic activity on LP-1/Cfz cells. Homoharringtonine treatment 
reduced the levels of TAZ and TEAD1 as well as the MM-protective proteins Nrf2 
and MCL1. Thus, our data suggest the importance of further studies evaluating 
translation inhibitors in relapsed/refractory MM. On the other hand, use of TJP1 as 
a MM biomarker for proteasome inhibitor sensitivity requires careful consideration. 
INTRODUCTION
Over the past decade, the prognosis of multiple 
myeloma (MM) patients has improved with the 
introduction of new drugs such as the first- and second-
generation proteasome inhibitors bortezomib and 
carfilzomib [1]. Unfortunately, however, MM patients 
routinely develop resistance to proteasome inhibitor-based 
therapies and eventually succumb to their disease [2-5]. 
Toward identification of novel agents that will overcome 
resistance to this class of anti-MM drugs, we have 
developed isogenic models of carfilzomib resistance using 
a panel of patient-derived MM cell lines [6-9]. Our studies 
have revealed upregulated expression of the ABCB1/P-
glycoprotein multidrug resistance efflux transporter, 
elevated prosurvival autophagy and antioxidant defense, 
altered intermediary metabolism and reprogramming of 
the translation machinery as key processes mediating 
acquired resistance to carfilzomib [6-9].
Recently, Orlowski and colleagues reported that 
relative resistance to bortezomib and carfilzomib in some 
MM cell lines was associated with decreased expression 
of the tight junction protein 1 gene TJP1 (also known 
as zonula occludens 1, ZO-1) and they proposed that 
high TJP1 expression might be used as a biomarker of 
proteasome inhibitor sensitivity in the clinic [10]. In line 
with this, we observed that TJP1 transcript levels were 
decreased in two of our carfilzomib-resistant MM cell 
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lines compared to their parental counterparts (KMS-11/
Cfz and KMS-34/Cfz versus KMS-11 and KMS-34 cells, 
respectively; GEO: GSE69078). In contrast, we noted that 
carfilzomib-adapted LP-1/Cfz cells — also cross-resistant 
to bortezomib — expressed higher TJP1 transcript levels 
than parental LP-1 cells (GEO: GSE78069) [8]. 
Here we confirm that TJP1 protein levels are 
increased in LP-1/Cfz cells. Moreover, increased TJP1 
expression delineated a subset of relapsed/refractory MM 
patients on bortezomib-based therapy [11] sharing an 
LP-1/Cfz-like phenotype characterized by an adult tissue 
stem cell signature [12] and activation of interacting 
transcriptional effectors of the Hippo signaling cascade: 
TAZ (transcriptional co-activator with PDZ-binding motif 
encoded by the WWTR1 gene) and TEAD1 (TEA domain 
transcription factor 1) [13-16].
TAZ shares ~50% identity with YAP1 (Yes 
associated protein 1), another downstream effector of the 
Hippo pathway that intriguingly had previously been found 
to be homozygously deleted or generally downregulated in 
MM [17]. There are several structural differences between 
TAZ and YAP1 that are likely related to their overlapping 
yet distinct functional properties [13, 18]. Furthermore, 
it is becoming increasingly appreciated that TAZ activity 
is regulated by multiple inputs in addition to the Hippo 
kinase cascade, including cell morphology and mechanical 
cues from the extracellular microenvironment [19, 20]. 
siRNA-mediated knockdown of TJP1 or TAZ/
TEAD1 partially sensitized LP-1/Cfz cells to carfilzomib. 
Our in vitro findings were supported by an independent 
clinical data set [21] where MM patients with the LP-1/
Cfz-like molecular phenotype — i.e, high TJP1, WWTR1/
TAZ and TEAD1 expression — was associated with 
inferior overall survival outcomes. 
To identify novel agents that would potentially 
overcome resistance to this class of anti-MM drugs, we 
performed Connectivity Map (CMap) analysis [22] and 
uncovered translation inhibitors whose gene expression 
perturbations were significantly anticorrelated with 
the expression signatures shared by LP-1/Cfz cells 
and the relapsed/refractory MM cases with increased 
TJP1 expression. We confirmed the CMap prediction 
by showing that homoharringtonine (omacetaxine 
mepesuccinate) — the first translation inhibitor to be 
approved by the U.S. Food and Drug Administration — 
displayed potent cytotoxic activity on LP-1/Cfz cells. 
Cytotoxicity was associated with decreased TAZ and 
TEAD1 protein levels as well as two proteins, Nrf2 
and MCL1, previously identified by us and others as 
contributing to MM drug resistance [8, 9, 23-25]. 
RESULTS AND DISCUSSION
TJP1 is associated with drug resistance in LP-1/
Cfz and RPMI-8226/Dox40 MM cells
In prior work, we found that the transcription factor 
NF-E2 p45-related factor 2 (Nrf2; gene symbol NFE2L2) 
contributes to the carfilzomib-resistant phenotype in LP-1/
Cfz cells characterized by an epithelial-to-mesenchymal 
transition (EMT)-like expression signature [8]. EMT 
is a developmental program that is often activated 
during tumor metastasis resulting in the gain of stem 
cell properties by the malignant cells [26]. During 
developmental EMT, epithelial intercellular junctions 
are disrupted and TJP1 is coordinately downregulated 
with CDH1 (E-cadherin) [27]. Cell surface expression of 
E-cadherin was decreased on LP-1/Cfz cells compared 
to parental LP-1 cells [8], but TJP1 protein levels were 
predicted to be ~2-fold increased (Table S1: Expression 
changes, TJP1 202011_at probe set). Of potential 
relevance in this regard, upregulation of TJP1 has been 
associated with invasion and metastasis in certain tumor 
systems [28-30]. 
Western blot analysis showed significantly higher 
TJP1 levels in LP-1/Cfz compared to parental LP-1 cells 
(Figure 1). For comparison, we also examined TJP1 
levels in RPMI-8226 MM cells analyzed by Orlowski and 
colleagues [10] together with three drug-resistant RPMI-
8226 derivatives: RPMI-8226/Dox40 cells, selected for 
resistance to doxorubicin [31]; RPMI-8226/LR5 cells, 
Figure 1: TJP1 protein levels are increased in 
carfilzomib-resistant LP-1/Cfz cells. Western blot analysis 
showing significantly higher TJP1 levels in LP-1/Cfz compared 
to parental LP-1 cells. Note that TJP1 levels are also increased in 
doxorubicin-resistant RPMI-8226/Dox40 compared to parental 
RPMI-8226 cells.
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selected for resistance to melphalan [32]; and RPMI-8226/
MR20 cells, selected for resistance to mitoxantrone [33]. 
TJP1 levels were increased in RPMI-8226/Dox40 cells; 
however, no significant changes were observed in the 
other derivatives (Figure 1). This was noteworthy because 
we and others have shown that RPMI-8226/Dox40 cells 
are cross-resistant to both carfilzomib and bortezomib 
due in part to upregulation of ABCB1/P-glycoprotein [6, 
34]. These results indicated that overexpression of TJP1 
in MM cells is not universally associated with increased 
sensitivity to proteasome inhibitors. Consequently, 
we were interested in determining whether there were 
instances where MM patients who developed resistance 
to proteasome inhibitor-based therapies also exhibited 
increased TJP1 expression and whether they might share 
similar properties with LP-1/Cfz or RPMI-8226/Dox40 
cells. 
Increased TJP1 expression during disease 
progression identifies a subset of relapsed/
refractory MM patients on bortezomib-based 
therapy exhibiting an LP-1/Cfz-like phenotype
We first examined TJP1 levels in the GEO: 
GSE31161 data set that contains expression profiling 
data at diagnosis and relapse for MM patients treated 
with the University of Arkansas for Medical Sciences 
(UAMS) Total Therapy (TT3) protocol which incorporates 
bortezomib up-front into the Total Therapy 2 (TT2) 
tandem transplant regimen [11]. Out of 30 evaluable 
patients, 13 (43.3%) had significantly higher TJP1 
expression at relapse (TJP1-up patients: ~6.5-fold up; 
log
2
FC for the TJP1 202011_at probe set, 2.70; P = 7.63 
× 10-4) and 17 (56.7%) had significantly lower TJP1 
expression at relapse (TJP1-down patients: ~3.7-fold 
Figure 2: Increased expression of TJP1 is associated with upregulation of TAZ-TEAD activity and adult stem cell genes 
in LP-1/Cfz cells and TT3 protocol patients with relapsed/refractory disease (GEO: GSE31161). A. GSEA enrichment 
plots of the Cordenonsi YAP Conserved Signature for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with 
increased TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). B. GSEA enrichment plots 
of the Wong Adult Tissue Stem Module for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with increased 
TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). NES, normalized enrichment score.
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down; log
2
FC for the TJP1 202011_at probe set, -1.88; 
P = 3.98 × 10-3) (Table S1: Expression changes). Neither 
group had increased ABCB1 expression at relapse (Table 
S1: Expression changes, ABCB1 209993_at probe set).
Next we applied Gene Set Enrichment Analysis 
(GSEA) to compare the two TT3 patient subsets with 
LP-1/Cfz cells [35]. Similar to LP-1/Cfz cells, significant 
enrichment of an EMT-like signature (Hallmark Epithelial 
Mesenchymal Transition) was observed for TJP1-up 
patients (normalized enrichment score [NES] = 1.78, P 
< 0.001) (Table S1: Hallmark collection). Also, as with 
LP-1/Cfz cells, significant enrichment of an Nrf2 target 
gene set (NFE2L2.V2) was found for TJP1-up patients 
(NES = 1.43, P < 0.001) (Table S1: C6 Oncogenic 
signatures). Interestingly, LP-1/Cfz cells and both TT3 
patient subsets showed enrichment of the Cordenonsi YAP 
Conserved Signature associated with cancer stem cell-
related properties (Figure 2A; Table S1: C6 Oncogenic 
signatures). Notably, among the 3,400 gene sets in the 
C2.CGP Chemical and genetic perturbations collection, 
the Wong Adult Tissue Stem Module, containing genes 
coordinately upregulated in a compendium of adult tissue 
Figure 3: TAZ-TEAD1 activation in LP-1/Cfz cells confers resistance to carfilzomib. A. TAZ levels are increased in LP-1/
Cfz (Cfz) versus parental LP-1 cells (1.6 ± 0.3-fold, n = 10, P < 0.01). Cells were pretreated with MG-132 (15 μM) for 18 hours to prevent 
proteasomal degradation. B. TEAD1 levels are increased in LP-1/Cfz (Cfz) versus parental LP-1 cells (2.2 ± 0.3-fold, n = 10, P < 0.01). 
Cells were pretreated with MG-132 (15 μM) for 18 hours to prevent proteasomal degradation. C. siRNA-mediated knockdown of TAZ 
slightly sensitized LP-1/Cfz cells to carfilzomib. Consistent with low YAP1 levels in LP-1/Cfz cells, siRNA-mediated knockdown of YAP1 
in concert with TAZ did not meaningfully enhance sensitization of the cells to the drug. LP-1/Cfz cells were significantly sensitized to 
carfilzomib by combined siRNA-mediated knockdown of TAZ and TEAD1. No effects were observed on parental LP-1 cells under any of 
the conditions. Cells were treated with carfilzomib (12.5 nM) for 48 hours after transient transfection and cell viability was determined by 
alamarBlue assay. *, P = 0.04 vs negative siRNA control (siNeg, n = 3). D, E. siRNA-mediated knockdown of TAZ and TEAD1 in LP-1/
Cfz cells was accompanied by decreased TAZ (40 ± 15% decrease) (D) and TEAD1 (57 ± 6% decrease) (E) levels.
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stem cells [12], was enriched in both LP-1/Cfz cells and 
TJP1-up patients (Figure 2B). Conversely, TJP1-down 
patients had negative enrichment of this gene set (Figure 
2B) and instead had enrichment of an embryonic stem cell-
like signature (Wong Embryonic Stem Cell Core; NES = 
3.42; P < 0.001) [12]. Collectively, the results indicated 
that the 30 MM cases that progressed on bortezomib-based 
TT3 therapy had acquired transcriptional programs shared 
with stem cells. Increased TJP1 expression delineated 
a TT3 subset most closely resembling LP-1/Cfz cells: 
i.e., exhibiting EMT-like features, Nrf2 activation and 
enrichment of an adult tissue stem cell signature.
Elevated TAZ and TEAD1 protein levels provide 
an explanation for the Cordenonsi YAP Conserved 
Signature in LP-1/Cfz cells
The Cordenonsi YAP Conserved Signature, 
representing a list of evolutionary conserved target 
genes of the YAP1 transcriptional effector of the Hippo 
signaling pathway, was the top-ranked gene set for LP-1/
Cfz cells (Table S1: C6 Oncogenic signatures). We had 
not focused on it earlier because, as previously reported 
for most MM and other hematopoietic cancer cells [17], 
YAP1 mRNA levels were low in LP-1 cells and were not 
increased in LP-1/Cfz cells (~1.2-fold down; log
2
FC for 
the YAP1 213342_at probe set, -0.24; P = 0.14) (Table 
S1: Expression changes). Upon further investigation, we 
learned that the Cordenonsi YAP Conserved Signature 
was enriched in breast cancer cells undergoing EMT that 
resulted in the activation of TAZ, a paralog of YAP1, 
which conferred stem cell-like properties on the tumor 
cells [36]. Slightly increased expression of the TAZ-
encoding gene WWTR1 was observed in LP-1/Cfz cells 
(~1.3-fold up; log
2
FC for the WWTR1 202133_at probe 
set, 0.41; P = 0.05) (Table S1: Expression changes). In 
addition, TEAD1, a key DNA-binding transcription factor 
partner of TAZ [14, 15], was highly expressed in both 
LP-1 and LP-1/Cfz cells (TEAD1 224955_at probe set; 
GEO: GSE78069). As anticipated [17], YAP1 protein 
levels were low in LP-1 cells (below detection by western 
blotting). Although WWTR1/TAZ mRNA levels were 
comparable to YAP1 mRNA levels (GEO: GSE78069), 
TAZ protein could be detected in LP-1 cells and elevated 
levels were observed in LP-1/Cfz cells (Figure 3A). 
Strikingly, TEAD1 protein levels were also markedly 
increased in LP-1/Cfz cells (Figure 3B). These findings 
were reminiscent of the translational upregulation we 
previously documented for Nrf2 in LP-1/Cfz cells [8, 9]. 
Importantly, combined knockdown of TAZ and TEAD1 
with previously validated siRNAs [37, 38] partially 
sensitized LP-1/Cfz cells to carfilzomib (P = 0.04; Figure 
3C-E).
Increased TJP1 expression separates out MM 
patients with poor prognosis into a higher-risk 
LP-1/Cfz-like subset
Acquisition of EMT-like features was previously 
shown to promote the extramedullary dissemination 
of MM cells [39]. Gene profiling of extramedullary 
MM has revealed differential expression of adhesion 
molecules and factors that stimulate angiogenesis [40]. 
In this regard, significant enrichment of an angiogenesis 
signature (Hallmark Angiogenesis) was observed for 
both LP-1/Cfz cells and for TJP1-up patients (NES = 
1.68, P < 0.001 and NES = 1.92, P < 0.001, respectively) 
(Table S1: Hallmark collection). Moreover, we noted that 
WWTR1/TAZ was included among the 156 upregulated 
genes in extramedullary MM [40]. A separate gene 
expression profiling study conducted by the UAMS group 
showed that extramedullary MM was more prevalent 
in patients with high-risk disease that includes those in 
the proliferation-related “PR” subgroup [41]. The PR 
subgroup was previously defined in an independent 
cohort of newly diagnosed patients treated on UAMS 
TT2 and TT3 protocols (GEO: GSE2658) [21]. We used 
the PROGgeneV2 prognostic biomarker identification 
tool to investigate the impact of TJP1 expression on the 
overall survival outcomes of MM patients in the GEO: 
GSE2658 data set [42]. Using median gene expression 
values as bifurcation points, Cox proportional hazards 
regression analysis showed that MM patients in the PR 
subgroup with the Cordenonsi YAP Conserved Signature 
(57 genes) had significantly inferior overall survival, 
with worse prognosis when high level TJP1 coexpression 
was also considered (Figure 4A). High expression of 
the top 50 genes in the leading edge subset of the LP-1/
Cfz Wong Adult Tissue Stem Module (721 genes total) 
was also associated with adverse outcomes. Within these 
parameters, TJP1 expression levels did not provide any 
additional prognostic information (Figure 4B). 
Only 2 out of the top 50 genes in the leading edge 
subset of the LP-1/Cfz Wong Adult Tissue Stem Module 
are shared with the Cordenonsi YAP Conserved Signature: 
ITGB5 and CRIM1, which were also among the 156 
upregulated genes in extramedullary MM [40]. ITGB5, 
encoding β5-integrin, was previously demonstrated to 
play a critical role in EMT associated with the tumorigenic 
potential of breast cancer cells [43]. CRIM1 encodes 
cysteine rich transmembrane bone morphogenetic protein 
regulator 1, which has been shown to regulate integrin 
signaling and angiogenesis during development [44, 45]. 
Increased expression of both genes has been associated 
with the acquisition of chemoresistance [46, 47]. Notably, 
ITGB5 and CRIM1 are coexpressed with WWTR1/TAZ (top 
20 gene neighbors) across 947 cell lines in the Cancer Cell 
Line Encyclopedia (CCLE; Figure S1) [48]. Furthermore, 
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Figure 4: Prognostic value of TJP1 expression in MM patient survival outcomes. KaplanMeier survival plots of 47 MM 
patients in the high-risk PR subgroup (GEO: GSE2658) created using PROGgeneV2: A. Cordenonsi YAP Conserved Signature minus (left) 
and plus (right) TJP1 coexpression. B. Leading edge subset (top 50 genes) of the LP-1/Cfz Wong Adult Tissue Stem Module minus (left) 
and plus (right) TJP1 coexpression. C. WWTR1/TAZ expression (left) plus coexpression of TEAD1, ITGB5, CRIM1 and TJP1 (right). 
Median gene expression values were used as bifurcation points.
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TJP1 is among the top 20 gene neighbors of both TEAD1 
and ITGB5 in the CCLE (Figure S1). Kaplan-Meier plots 
indicated significant segregation in survival outcomes for 
patients in the PR subgroup with high versus low WWTR1/
TAZ expression (hazard ratio, HR = 2.7; 95% confidence 
interval/CI, 1.34-5.44; P = 0.006). Increasing risk of 
mortality was observed when high level coexpression of 
TEAD1, ITGB5 and CRIM1 (HR = 3.98; 95% CI, 1.63-
9.68; P = 0.002) and TEAD1, ITGB5, CRIM1 plus TJP1 
were also taken into consideration (HR = 7.37; 95% CI, 
1.96-27.67; P = 0.003) (Figure 4C). It should be mentioned 
that high level expression of TEAD1 had previously been 
associated with high-risk disease and the PR subgroup 
in MM [49]. However, the biological relevance of this 
observation has not been heretofore appreciated.
Increased TJP1 expression contributes to LP-1/
Cfz-like high-risk MM phenotype and carfilzomib 
resistance
Although TJP1 was not identified as a YAP/TAZ 
target gene in the Cordenonsi YAP Conserved Signature, 
it was a member of the top two overlapping gene sets in 
the MSigDB C5.CC Gene Ontology Cellular Component 
collection (580 total gene sets): GO Cell Junction (13 out 
of 57 genes; P = 1.26 × 10-9) and GO Anchoring Junction 
(9 out of 57 genes; P = 9.30 × 10-9) (Figure 5A). Both 
gene sets were selectively enriched in LP-1/Cfz cells and 
TJP1-up patients (Figure 5B; Table S1: C5 GO gene sets). 
Conversely, TJP1-down patients had negative enrichment 
of these gene sets (Figure 5B; and data not shown). 
Moreover, ITGB5 was included with TJP1 in the LP-1/
Cfz leading edge subset of the GO Anchoring Junction 
gene set (Figure 5C). Indeed, enrichment of canonical 
pathways and GO-term gene sets involving cell contacts 
— previously noted to be overrepresented within the 
TAZ interactome data set [18] — was observed for LP-1/
Cfz cells and TJP1-up patients (Figure 5A,D; Table S1: 
C2.CP Canonical pathways, C5 GO gene sets), suggesting 
biological relevance of TJP1 upregulation [19, 20]. 
To further explore the potential functional 
significance of increased TJP1 expression with respect to 
the LP-1/Cfz-like high-risk MM phenotype, we stratified 
the 30 TT3 relapsed samples in the GEO: GSE31161 data 
set on the basis of TJP1 expression (TJP1 202011_at 
probe set). While the samples did not perfectly segregate 
into two separate groups, those with the highest TJP1 
mRNA levels belonged to the TJP1-up subset (increased 
TJP1 expression at relapse) and those with the lowest 
TJP1 mRNA levels belonged to the TJP1-down subset 
(decreased TJP1 expression at relapse) (Figure 6A). 
When we performed GSEA to identify gene sets that 
positively correlated with TJP1 expression, we found that 
the Cordenonsi YAP Conserved Signature, the Wong Adult 
Tissue Stem Module and the GO Anchoring Junction 
gene sets were all significantly enriched (Figure 6B). 
Significant enrichment of the Cordenonsi YAP Conserved 
Signature was previously observed after development of 
chemoresistance in melanoma cells [50]. In that study, in 
which TJP1 was one out of 426 significantly upregulated 
genes common to two cell lines selected for resistance to 
the BRAF inhibitor PLX4032 (vemurafenib) (see Table 
EV1 of ref. [50]), increased YAP/TAZ transcriptional 
activity was accompanied by enhanced YAP/TAZ nuclear 
localization. 
In line with this, TAZ predominantly localized to 
the nucleus in a characteristic punctate staining pattern 
[13] as well as to the perinuclear region of LP-1/Cfz 
cells (Figure 7A, top panels). Lower levels of TAZ were 
present in parental LP-1 cells with a greater distribution 
in the perinuclear region (Figure 7A, bottom panels). By 
comparison, TJP1 was present in the cytoplasm, plasma 
membrane and nucleus of LP-1/Cfz cells (Figure 7A, top 
panels) whereas it was primarily detected in the cytoplasm 
of parental LP-1 cells (Figure 7A, bottom panels). Some 
colocalization of TJP1 with TAZ was observed in LP-1/
Cfz cells but not within the punctate nuclear structures. 
These results indicated that, while TJP1 is able to bind to 
TAZ in vitro [51], functional complexes between TJP1 and 
TAZ are not responsible for TAZ nuclear retention [52, 
53].
To directly test whether TJP1 contributes to 
carfilzomib resistance, we transfected LP-1/Cfz cells 
with two previously validated TJP1 siRNAs [54, 55]. 
We confirmed that both siRNAs resulted in a significant 
decrease in TJP1 protein levels (64 ± 4% decrease; n = 
3) (Figure 7B). As illustrated in Figure 7C, knockdown 
of TJP1 with both siRNAs modestly, but significantly, 
sensitized LP-1/Cfz cells to carfilzomib (P = 0.03).
Translation inhibitors as potential treatment for 
relapsed/refractory MM
Consistent with the post-transcriptional increase 
in TEAD1 (and, to some degree, TAZ) levels and the 
translational adaptations that resulted in increased Nrf2 
protein levels in LP-1/Cfz cells [8, 9], pathways related to 
translational control of gene expression were among the 
overrepresented processes shared with TJP1-up patients 
(Figures 5D, 6B; Table S1: C2.CP Canonical pathways, 
C5 GO gene sets). In a complementary approach, when we 
queried the Connectivity Map database (CMap Build 02), 
a reference collection of 6,100 gene expression signatures 
from four human cell lines treated with 1,309 small 
molecule perturbagens [22], we identified gene expression 
perturbations by cycloheximide and emetine as the only 
ones that were significantly negatively correlated with the 
expression signatures linked to both carfilzomib resistance 
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Figure 5: Gene Ontology terms and canonical pathways involving cell contacts are enriched in LP-1/Cfz cells and TT3 
protocol patients (GEO: GSE31161) with increased TJP1 levels at relapse. A. Bar graphs showing the top 10 gene sets out of 
580 total gene sets in the MSigDB C5.CC Gene Ontology Cellular Component collection that overlap with the Cordenonsi YAP Conserved 
Signature. P values were calculated using the hypergeometric distribution. See also Table S1: GO gene sets. B. GSEA enrichment plots of 
the GO Anchoring Junction gene set for triplicate samples of LP-1/Cfz versus parental LP-1 cells (top), for TT3 patients with increased 
TJP1 levels at relapse (middle), and for TT3 patients with decreased TJP1 levels at relapse (bottom). NES, normalized enrichment score. C. 
Heat map of the leading edge subset of genes in the GO Anchoring Junction gene set upregulated in LP-1/Cfz (Cfz) versus parental LP-1 
cells (triplicate samples). Probe sets for TJP1, ITGB5 and RND3 are highlighted. See text for details. D. Bar graphs showing the top 10 
gene sets out of 1329 total gene sets in the MSigDB C2.CP Canonical pathways collection that overlap with the GO Anchoring Junction 
gene set. Note that 5 out of the 10 gene sets involve translational control mechanisms. P values were calculated using the hypergeometric 
distribution. See also Table S1: C2.CP Canonical pathways.
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in LP-1/Cfz cells and the TJP1-up MM cases (P ≤ 0.05) 
(Table S1: CMap Build 02). These results suggested that 
translation inhibitors may modulate chemosensitivity 
of MM cells with these shared features by reversing the 
expression of the signature genes responsible [56, 57]. 
We tested emetine and found that it displayed single-
agent activity against LP-1/Cfz cells (Figure 8A, top). 
This result prompted us to examine the effect of the 
FDA-approved translation inhibitor homoharringtonine 
(omacetaxine mepesuccinate) [58], which had previously 
been demonstrated to induce apoptosis but had not been 
reported to overcome drug resistance in MM cells [59]. 
Treatment with homoharringtonine displayed potent 
cytotoxicity against LP-1/Cfz cells over a concentration 
range that was 10-fold lower than that of emetine (Figure 
8A, bottom). During revision of this manuscript, a 
new version of the CMap database was released that 
is accessible via CLUE (CMap and LINCS Unified 
Environment: [clue.io]). The Touchstone dataset of 
CLUE contains ~50,000 gene expression signatures from 
nine human cell lines treated with 2,911 FDA-approved 
and clinical trial drugs. It was especially noteworthy 
Figure 6: Enriched MSigDB gene sets in MM patients enrolled on the TT3 protocol with high TJP1 levels at relapse. 
A. Heat map of TJP1 neighbors for 30 TT3 relapsed samples in the GEO: GSE31161 data set stratified on the basis of TJP1 202011_at 
probe set levels. Asterisks indicate TJP1-up patients (see Table S1: GSE31161, TT3 samples). B. Enrichment plots of selected gene sets 
containing genes whose expression is highly correlated with TJP1 expression. NES, normalized enrichment score.
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Figure 7: Subcellular localization and knockdown of TJP1 in LP-1/Cfz cells. A. LP-1/Cfz and parental LP-1 cells were 
cultured on poly-L-lysine-coated microscope slides. Cells were fixed and labeled with anti-TJP1 (Alexa Fluor 488, green) or anti-TAZ 
(Alexa Fluor 568, red) antibodies. Cell nuclei were stained with TOTO-3 (blue). B. siRNA-mediated knockdown of TJP1 mRNA was 
accompanied by decreased TJP1 levels (64 ± 4% decrease; n = 3). C. Knockdown of TJP1 mRNA using two specific siRNAs (siTJP1 #1, 
siTJP1 #2) sensitizes LP- 1/Cfz cells to carfilzomib. Cells were cultured on fibronectin-coated plates and treated with carfilzomib (6 nM) 
for 48 hours after transient transfection; cell viability was determined by alamarBlue assay. *, P = 0.03 vs negative siRNA control (siNeg, 
n = 3).
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therefore that expression signatures generated by 
homoharringtonine as well as emetine and cycloheximide 
— in fact, translation inhibitors in general — were among 
those displaying the most significant negative correlations 
with the LP-1/Cfz and TJP1-up MM signatures (Table S1: 
CMap CLUE). 
Translation inhibitors induce cell death by reducing 
the levels of short-lived prosurvival proteins like the 
BCL2 family member MCL1 [59]. TAZ is an unstable 
protein with a half-life of ~2 hours in other cell types 
[60]. Treatment of LP-1/Cfz cells with emetine or 
homoharringtonine led to reduced amounts of TAZ; the 
levels of TEAD1, which has a half-life of ~16 hours in 
fibroblasts [61], were also reduced under the 18-hour 
treatment conditions employed (Figure 8B). Nrf2 is also a 
short-lived protein [62], and Nrf2 levels were significantly 
reduced by both translation inhibitors (Figure 8C). 
Moreover, recent studies have provided additional support 
for an important role of MCL1 in MM cell survival [24, 
25] (ClinicalTrials.gov: NCT02675452, NCT02992483). 
Both emetine and homoharringtonine significantly reduced 
MCL1 levels (Figure 8C). 
Concluding remarks
A recent report by Orlowski and colleagues 
suggested the use of TJP1 as a biomarker to identify 
MM patients most likely to benefit from proteasome 
inhibitors [10]. The investigators proposed that high TJP1 
levels resulted in decreased proteasome activity due to 
suppression of expression of the PSMB8 gene encoding 
the immunoproteasome β5i/LMP7 (chymotrypsin-like) 
subunit targeted by carfilzomib and bortezomib as well 
as the PSMB9 gene encoding the β1i/LMP2 (caspase-
like) subunit that is also targeted by bortezomib [10]. This 
model does not hold for LP-1/Cfz cells nor for the subset 
of MM patients on bortezomib-based therapy analyzed 
here. In the case of LP-1/Cfz cells, PSMB8 and PSMB9 
were downregulated concomitant with increased TJP1 
expression (~1.5-fold; P = 2.71 × 10-5 and 1.58 × 10-5, 
respectively) but this was associated with acquisition of 
carfilzomib resistance, whereas there were no significant 
differences in PSMB8 or PSMB9 expression levels during 
disease progression in the TJP1-up patients (Table S1: 
PSMB8 209040_s_at and PSMB9 204279_at probe sets). 
Figure 8: Cytotoxic activity of translation inhibitors against LP-1/Cfz cells. A. Cells were treated with the indicated 
concentrations of emetine (top) or homoharringtonine (bottom) for 48 hours and cell viability was determined by alamarBlue assay. B. 
Treatment with emetine (0.3 µM) or homoharringtonine (30 nM) for 18 hours decreases TAZ (top) and TEAD1 (bottom) levels in LP-1/
Cfz cells. C. Treatment with emetine (0.3 µM) or homoharringtonine (30 nM) for 18 hours decreases Nrf2 (top) and MCL1 (bottom) levels 
in LP-1/Cfz cells.
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The molecular association between increased TJP1 
expression and TAZ/TEAD activation and exactly how 
this contributes to proteasome inhibitor resistance and 
the LP-1/Cfz-like high-risk MM phenotype remain to be 
clarified. A number of tight junction-associated signaling 
pathways have been described [63]. One possibility is that 
upregulated TJP1 expression activates TAZ similar to 
that previously reported for the PDZ domain-containing 
tight junction protein PARD3 which involves protein 
phosphatase 1 [64]. Another candidate effector for future 
study is Rnd3/RhoE, a multifunctional Rho family 
GTPase that acts both as a regulator of the cytoskeleton 
and translation initiation [65, 66]. Rnd3 participates in 
focal adhesion and tight junction formation together with 
TJP1 (Figure 5C) [67] as well as in tumor cell migration 
[68, 69]. We previously identified RND3 as a novel Nrf2-
upregulated target in LP-1/Cfz cells associated with 
the translational reprogramming leading to carfilzomib 
resistance [8, 9].
In any event, our data indicate the importance of 
additional patient stratification when considering use of 
TJP1 as a biomarker of proteasome inhibitor sensitivity 
in MM. On the other hand, our findings with translation 
inhibitors in LP-1/Cfz cells support further preclinical 
testing and potential clinical evaluation of these agents in 
relapsed/refractory MM.
MATERIALS AND METHODS
Cell culture
Carfilzomib-resistant LP-1/Cfz cells have been 
described previously [8]. RPMI-8226 cells were obtained 
from the American Type Culture Collection (Manassas, 
VA). Doxorubicin-resistant RPMI-8226/Dox40 cells 
[31], melphalan-resistant RPMI-8226/LR5 cells [32] and 
mitoxantrone-resistant RPMI-8226/MR20 cells [33] were 
kindly provided by Dr. William Dalton (Moffitt Cancer 
Center, Tampa, FL). Cells were cultured in RPMI 1640 
with GlutaMAX (Thermo Fisher Scientific) supplemented 
with 10% fetal bovine serum (Cambrex BioScience), 100 
U/ml penicillin and 100 μg/ml streptomycin. Cultures 
were maintained at 37°C in a humidified atmosphere 
containing 5% CO2.
Antibodies and reagents
The following antibodies were used: anti-ZO-1/
TJP1 (ZO1-1A12) (Fisher Scientific, Cat. No. 33-
9100); anti-TAZ (V386) (Cell Signaling Technology, 
Cat. No. 4883); anti-TEF-1(TEAD1) (Clone 31/TEF-1) 
(BD Biosciences, Cat. No. 610922); anti-Nrf2 (H-300) 
(Santa Cruz Biotechnology, Cat. No. sc-13032); anti-
MCL1 (S-19) (Santa Cruz Biotechnology, Cat. No: sc-
819); and anti-α-tubulin mouse mAb (DM1A) (EMD 
Millipore Corporation, Cat. No. CP06). Carfilzomib 
(Cat. No. A-1098) was obtained from Active Biochem; 
emetine (Cat. No. 32-469-3250MG) was purchased from 
Fisher Scientific; and homoharringtonine (omacetaxine 
mepesuccinate) (Cat. No. SML1091) was from Sigma-
Aldrich.
Confocal microscopy
Immunofluorescence confocal microscopy was 
performed essentially as described previously [7, 8]. 
In brief, cells were plated onto poly-L-lysine-coated 
microscope slides (Thermo Fisher Scientific, Cat. No. 50-
279-88) in 10 cm cell culture dishes (5 x 105 cells in 1 ml 
of medium per slide) [70]. After 3 hours, 10 ml of medium 
was added and the cells were cultured overnight. Attached 
cells were fixed in 3.7% formaldehyde for 5 minutes at 
room temperature and permeabilized with 0.5% Triton 
X-100 in phosphate-buffered saline (PBS) for 15 minutes 
at room temperature. Following permeabilization, the 
cells were rinsed with PBS and blocked in PBS containing 
10% goat serum and 0.01% Triton X-100 for 40 minutes 
at room temperature. The cells were then incubated with 
anti-TJP1 and anti-TAZ antibodies diluted 1:500 in PBS 
containing 1% goat serum and 0.01% Triton X-100 for 
1 hour at room temperature. The cells were rinsed three 
times with PBS and then incubated with Alexa Fluor 
488-conjugated goat anti-mouse (Thermo Fisher Scientific, 
Cat. No. A-11001) and Alexa Fluor 568-conjugated goat 
anti-rabbit (Thermo Fisher Scientific, Cat. No. A-11036) 
secondary antibodies diluted 1:500 in PBS containing 1 
μM TOTO-3 (Thermo Fisher Scientific, Cat. No. T3604), 
1% goat serum and 0.01% Triton X-100 for 1 hour at room 
temperature. The cells were rinsed with PBS and mounted 
with Fluoromount G (Electron Microscopy Sciences). 
Imaging analysis was performed on an LSM 710 laser 
scanning confocal microscope equipped with Zen software 
(Carl Zeiss Microscopy).
siRNA transfections
RNA interference was performed as described 
previously [8] using validated Silencer® Select siRNAs 
for WWTR1/TAZ (s24789) [37], TEAD1 (s13961) [38], 
YAP1 (s20366) [38], TJP1 (s14155, s14156) [54, 55] or 
a negative control siRNA (Cat. No. 4390843) (Thermo 
Fisher Scientific). Briefly, 2 x 106 cells per ml were seeded 
into 24 well plates in 100 μl aliquots. Each well received 
a mixture of siRNAs (750 ng) and HiPerFect reagent (6 
μl) in 100 μl serum-free culture medium preincubated for 
15 minutes. After 5 hours, the cells were diluted to 6 x 
105 per ml in complete medium. Cells (3 x 105 per ml) 
were seeded into 96 well plates and treated with a range 
of carfilzomib concentrations.
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Cytotoxicity assay
Cells were treated with carfilzomib and agents at the 
indicated concentrations and cell growth was measured 
using the alamarBlue cell viability and proliferation 
reagent (Thermo Fisher Scientific) as described previously 
[6-8], except that assays were performed on fibronectin-
coated plates (Fisher Scientific, Cat. No. 08-774-60) [71].
Gene expression analysis
Gene expression profiling data for LP-1/Cfz and 
parental LP-1 MM cells is available at GEO: GSE78069. 
Datasets for MM patients are available at GEO: GSE2658 
and GEO: GSE31161.
Gene set enrichment analysis (GSEA)
GSEA [26] was performed using the MSigDB v5.2 
collections. Statistical significance of the enrichment score 
was assessed by 1,000 gene set permutations.
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